Pronunciation: low-MUH-FLOX-uh-sin HIGH-droe-KLOR-ide
- Tablets 400 mg
Interferes with microbial DNA synthesis.
95% to 98% absorbed. T max is 0.8 to 1.4 h. C max is 0.8 mcg/mL, and AUC is 5.6 mcg•h/mL after 100 mg dose. Steady-state is achieved within 48 h. Food delays rate of absorption of drug; T max increased to 2 h and AUC is decreased 12%.
About 10% protein bound.
Minimally metabolized. Major metabolite is glucuronide (about 9% of administered dose).
The t ½ is about 8 h. About 65% of an oral dose is excreted unchanged in the urine. Mean renal Cl is 145 mL/min. About 10% is excreted unchanged in the feces.
Special PopulationsRenal Function Impairment
CrCl 10 to 40 mL/min/1.73 m 2
AUC is increased 335%; t ½ is increased to 21 h. Dose adjustment is warranted.CrCl less than 10 mL/min/1.73 m 2
AUC is increased 700%; t ½ is increased to 45 h. Dose adjustment is warranted.
Indications and Usage
Treatment of infections of the lower respiratory tract and urinary tract caused by susceptible organisms; prevention of UTIs in patients undergoing transurethral or transrectal procedures.
Dosage and AdministrationAdults
PO 400 mg every day for 3 to 14 days.Renal Function Impairment (CrCl 10 to 40 mL/min/1.73 m 2 )
Initial dose: 400 mg. Maintenance dose: 200 mg every day.Surgical Prophylaxis
PO (Transurethral surgical procedures) 400 mg 2 to 6 h preoperatively.Adults
PO (Transrectal prostate biopsy) 400 mg 1 to 6 h prior to procedure.
- Administer tablets with a full glass of water without regard to meals. Administer with food if GI upset occurs.
- Administer lomefloxacin either 2 h before or 4 h after sucralfate, antacids containing magnesium or aluminum, didanosine-buffered tablets or pediatric powder, or other products containing iron or zinc.
Store tablets at controlled room temperature (59° to 77°F).
Drug InteractionsAntineoplastic agents
Decreased lomefloxacin serum levels.Magnesium- or aluminum-containing antacids, iron salts, zinc salts, sucralfate, didanosine
Decreased oral absorption of lomefloxacin. Stagger administration times.Probenecid
Decreased renal elimination of lomefloxacin.
Laboratory Test Interactions
None well documented.
Headache (4%); dizziness (2%).
Nausea (4%); diarrhea, abdominal pain (1%).
Category C .
Undetermined; however, other fluoroquinolones have been shown to be excreted in breast milk.
Safety and efficacy not established.
Cl may be decreased.
Serious and potentially fatal reactions have occurred. Discontinue if allergic reaction occurs.
Reduced Cl may occur; adjust dose accordingly.
Use may result in bacterial or fungal overgrowth.
Not indicated for empiric treatment of acute bacterial exacerbation of chronic bronchitis when Streptococcus pneumoniae is the probable pathogen.
CNS stimulation can occur; use with caution in patients with known or suspected CNS disorders.
Moderate to severe phototoxic reactions have occurred when exposed to direct, indirect, and ultraviolet light.
Consider in patients who develop diarrhea.
Ruptures of the shoulder, hand, or Achilles tendon may occur. The risk may be increased in patients receiving corticosteroids, especially in the elderly.
Renal failure (severely decreased urine output, weight gain, confusion, dry flaky skin), tremor, seizures, dyspnea.
- Advise patient to read patient information leaflet before starting therapy and with each refill.
- Review dosing schedule and prescribed length of therapy with patient.
- Advise patient that medication can be taken with a full glass of water without regard to meals but to take with food if GI upset occurs.
- Advise patient to take each dose at least 12 h before exposure to the sun to reduce risk of photosensitivity reaction.
- Advise patient that if a dose is missed to take as soon as remembered. However, if it is nearing the time for the next dose, to skip the dose and take the next dose at the regularly scheduled time.
- Advise patient to take lomefloxacin either 2 h before or 4 h after sucralfate, antacids containing magnesium or aluminum, didanosine-buffered tablets or pediatric powder, or other products containing iron or zinc.
- Remind patient to complete entire course of therapy, even if symptoms of infection have disappeared.
- Advise patient to inform health care provider if infection does not appear to be improving or is getting worse.
- Advise patient to drink fluids liberally (eg, eight 8 oz glasses of water daily) while taking this medication.
- Advise patient to discontinue therapy and contact health care provider immediately if skin rash, hives, itching, shortness of breath, palpitations, fainting, or pain, tenderness or rupture of tendon occur.
- Advise patient to report the following signs of superinfection to health care provider: black furry tongue, white patches in mouth, foul-smelling stools, vaginal itching or discharge.
- Warn patient that diarrhea containing blood or pus may be a sign of a serious disorder and to seek medical care if noted and not treat at home.
- Caution patient that drug may cause dizziness and lightheadedness and to use caution while driving or performing other tasks requiring mental alertness until tolerance is determined.
- Advise patient to avoid unnecessary exposure to direct and indirect sunlight or tanning lamps, to use sunscreen, and wear protective clothing to avoid photosensitivity reactions during therapy and for several days after stopping medication. Advise patient to discontinue therapy and notify health care provider if any of the following occur following exposure to sunlight or artificial UV light (eg, sunlamp): sensation of skin burning, redness, swelling, blistering; rash or itching.